Disclaimer: This article is intended for informational purposes only. Imperial Peptides UK products are supplied strictly for Research Use Only (RUO) and are not for human or veterinary consumption.
At Imperial Peptides UK, we believe analytical transparency is essential to responsible peptide supply.
During routine third-party verification of Batch GHK50-03/28, independent testing identified that the batch was underfilled relative to the nominal 50mg specification.
While purity results remained high, the reported content did not meet our expected fill standard.
Why We Chose to Publish the Results
Rather than withholding the results, we chose to publish the full analytical documentation and clearly identify the batch with an advisory notice.
Pricing for this batch has also been adjusted accordingly to reflect the reported content discrepancy.
We believe researchers should have access to accurate batch-specific data in order to make informed purchasing decisions.
- Independent third-party verification completed
- Purity results remained high
- Reported fill did not meet nominal 50mg specification
- Batch published with advisory notice and adjusted pricing
Our Approach to Transparency
We believe transparency only has value when results are published consistently — not selectively.
Independent analytical testing is intended to verify batch quality objectively, including when results identify deviations from expected specifications.
All associated Certificates of Analysis for Batch GHK50-03/28 remain publicly available through our CoAs page .
Continuous Quality Review
Batch verification and supplier review remain ongoing parts of our quality control process.
Analytical transparency and batch traceability continue to play an increasingly important role across the UK research peptides market.
- Independent third-party verification
- Batch transparency
- Research-focused quality standards
- Continuous supplier review and quality control
Final Thoughts
Publishing batch-specific analytical findings — including when results identify discrepancies — remains an important part of maintaining transparent research supply standards.
We believe researchers should always have access to the same analytical information used during internal quality review processes.
As transparency standards continue to evolve within the UK peptide market, independently verified documentation remains increasingly important for supplier accountability.
Transparency and analytical consistency remain central to responsible peptide sourcing.
Imperial Peptides UK was built around a simple principle: researchers should be able to see exactly what they’re buying, how it was tested, and which batch it came from.
Independent testing only has value when the results are published transparently and applied consistently across all batches.
Imperial Peptides UK operates within the wider Imperial Sciences platform. All products are supplied strictly for Research Use Only. Not for human or veterinary use.
